Answers are grounded in this paper and cite their sources.
GONORRHEA remains the most frequently reported infectious disease in the United States. Antimicrobial resistance in the gonococcus continues to evolve, and coinfection withChlamydia trachomatisis a serious problem. Therefore, the periodic review of current therapies for gonorrhea to ensure effective treatment must be a major objective of the National Gonorrhea Control Program in the United States. In the past five years, the number of potentially useful antimicrobial agents for the treatment of gonococcal infections has proliferated: these include second- and third-generation cephalosporins, regimens combining the β-lactamase inhibitors clavulanic acid and sulbactam with penicillin and amoxicillin, and the quinolones. This article reviews (1) recent trends in gonococcal antimicrobial resistance and in vitro susceptibility to established and experimental regimens; (2) coinfection due toC trachomatisandNeisseria gonorrhoeaewithin the past five years; (3) therapy for incubating syphilis and gonorrhea; (4) prophylaxis of sexual partners exposed to resistant organisms; and (5)
No takes yet. Share an insight, caveat, or question.
R J Rice (1986) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: